Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1561 to 1570 of 1856 total matches.

Deep Brain Stimulation for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 06, 2009  (Issue 1309)
PD (mean disease duration 12.4 years). Patients who received DBS gained a mean of 4.6 hours/day ...
Deep brain stimulation (DBS) is increasingly used to treat advanced Parkinson's disease (PD), but few controlled clinical trials have been published. New evidence from a large controlled study has recently become available.
Med Lett Drugs Ther. 2009 Apr 6;51(1309):26-7 |  Show IntroductionHide Introduction

Drugs for Hypertriglyceridemia

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2013  (Issue 1411)
1. Wholesale acquisition cost (WAC) of 30 days’ treatment with the highest recommended usual adult ...
Fibrates, niacin and fish oil are promoted for treatment of hypertriglyceridemia. HMG-CoA reductase inhibitors (statins) can lower elevated serum concentrations of triglycerides, but less so than fibrates, niacins or fish oil. Lifestyle changes such as weight reduction, exercise and decreasing alcohol intake can also lower serum triglyceride levels and should be tried first.
Med Lett Drugs Ther. 2013 Mar 4;55(1411):17-9 |  Show IntroductionHide Introduction

Fluticasone Furoate (Arnuity Ellipta) for Asthma

   
The Medical Letter on Drugs and Therapeutics • May 25, 2015  (Issue 1469)
dosing instructions. 2. Approximate WAC for 30 days’ treatment at the lowest usual adult dosage. WAC ...
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta2-agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.
Med Lett Drugs Ther. 2015 May 25;57(1469):76-9 |  Show IntroductionHide Introduction

Ocrelizumab (Ocrevus) for MS

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2017  (Issue 1523)
every lymphopenia with interferon beta-1b Betaseron (Bayer) other day 86,895.70 Extavia (Novartis ...
The FDA has approved ocrelizumab (Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first anti-CD20 monoclonal antibody to be approved for treatment of MS and the first disease-modifying drug to be approved in the US for primary progressive MS.
Med Lett Drugs Ther. 2017 Jun 19;59(1523):98-101 |  Show IntroductionHide Introduction

Penbraya: A Pentavalent Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024  (Issue 1698)
the 30 days after vaccination. PREGNANCY AND LACTATION — Penbraya has not been studied in pregnant ...
The FDA has licensed Penbraya (Pfizer), a pentavalent polysaccharide conjugate meningococcal vaccine, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penbraya is the only meningococcal vaccine that contains all five of these serogroups. Two quadrivalent polysaccharide conjugate meningococcal vaccines containing serogroups A, C, W, and Y (MenACWY; Menveo, MenQuadfi) and two meningococcal serogroup B vaccines (MenB; Bexsero, Trumenba) are available in the US (see Table...
Med Lett Drugs Ther. 2024 Mar 18;66(1698):43-5   doi:10.58347/tml.2024.1698b |  Show IntroductionHide Introduction

Drugs for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025  (Issue 1719)
) $2100.00 Pegcetacoplan – 15 mg/0.1 mL q25-60 days Syfovre (Apellis) 2190.00 1. A topical microbicide ...
Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).
Med Lett Drugs Ther. 2025 Jan 6;67(1719):1-5   doi:10.58347/tml.2025.1719a |  Show IntroductionHide Introduction

Treatment of Xerostomia

   
The Medical Letter on Drugs and Therapeutics • Jul 29, 1988  (Issue 771)
agonist pilocarpine, 5 mg to 30 mg, divided into one to four oral doses per day, has been reported ...
Xerostomia, dry mouth due to decreased or absent saliva, is a common problem, particularly among elderly patients. Decreased salivary flow can be due to many different conditions, including drug therapy, Sj gren's syndrome (keratoconjunctivitis sicca) or radiation of the salivary glands.
Med Lett Drugs Ther. 1988 Jul 29;30(771):74-6 |  Show IntroductionHide Introduction

The Cervical Cap

   
The Medical Letter on Drugs and Therapeutics • Oct 07, 1988  (Issue 776)
for several days. CONCLUSION — The Prentif cervical cap is about as effective as a diaphragm, but remains ...
The US Food and Drug Administration recently approved the marketing of a cervical cap (Prentif Cavity-Rim Cervical Cap - Lamberts Ltd, England), a contraceptive device that has been used in one form or another for many years (JP Koch, Contraception, 25:161, 1982). The cap is being distributed in the USA and Canada by Cervical Cap (CxC), Ltd, PO Box 38003-292, Los Gatos, CA 95031, telephone 408-358-6264; the distributor will make the caps available only to practitioners who have attended training seminars.
Med Lett Drugs Ther. 1988 Oct 7;30(776):93-4 |  Show IntroductionHide Introduction

Clomipramine for Obsessive Compulsive Disorder

   
The Medical Letter on Drugs and Therapeutics • Nov 04, 1988  (Issue 778)
, especially nausea. Initial dosage is 25 mg once a day, taken in the evening, which can be increased ...
Clomipramine (Anafranil - Ciba-Geigy), a tricyclic antidepressant, is now available for treatment of obsessive compulsive disorder (OCD) in accordance with the new US Food and Drug Administration (FDA) procedure for promising investigational drugs (FE Young et al, JAMA, 259:2267, 1988). In other countries, clomipramine has been widely used for many years for treatment of depression.
Med Lett Drugs Ther. 1988 Nov 4;30(778):102-4 |  Show IntroductionHide Introduction

Capsaicin - A Topical Analgesic

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 1992  (Issue 873)
into the affected area of the skin three to four times a day, avoiding contact with the eyes and damaged skin. One ...
Capsaicin, a vanillyl alkaloid found in hot peppers and related plants, is now available without a prescription as Zostrix-HP (GenDerm) for topical relief of pain due to diabetic neuropathy, herpes zoster, or arthritis. The new formulation contains 0.075% capsaicin; the drug was previously available in a 0.025% concentration as Zostrix.
Med Lett Drugs Ther. 1992 Jun 26;34(873):62-3 |  Show IntroductionHide Introduction